Objective Considering the alarming rate of diabetic patients becoming blind after retinal edema formation, and the important risks of ocular complications due to the low specificity of the current glucocorticoid (GC) treatment, it is imperative to bring together all the necessary means for the development of novel therapies with better specificity, efficiency and limited secondary effects. To that end, it is crucial to fill the gap in the fundamental knowledge of diabetic macular edema (DME) physiopathology. By taking advantage of an existing beneficial but imperfect anti-edematous therapy (low specificity), we propose to use state-of-the-art methods to perform a wide and unique study on the mechanisms i) involved in diabetic retinopathy ii) and regulated by the corticosteroids, with the aim to potentiate the therapeutic effect of GCs, for a real restoration of vision in DME patients. Fields of science medical and health sciencesclinical medicineendocrinologydiabetesmedical and health sciencesclinical medicineophthalmologyretinopathy Programme(s) FP7-PEOPLE - Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013) Topic(s) FP7-PEOPLE-2009-RG - Marie Curie Action: "Reintegration Grants" Call for proposal FP7-PEOPLE-2010-RG See other projects for this call Funding Scheme MC-ERG - European Re-integration Grants (ERG) Coordinator INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE EU contribution € 45 000,00 Address RUE DE TOLBIAC 101 75654 Paris France See on map Region Ile-de-France Ile-de-France Paris Activity type Research Organisations Administrative Contact Mihaja Auguste (Ms.) Links Contact the organisation Opens in new window Website Opens in new window Total cost No data
